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Abstract: Osteoarthritis (OA) is a degenerative and inflammatory joint disorder with cartilage
loss. Dental pulp stem cells (DPSCs) can undergo chondrogenic differentiation and secrete growth
factors associated with tissue repair and immunomodulation. Leukocyte- and platelet-rich fibrin
(L-PRF) emerges in regenerative medicine because of its growth factor content and fibrin matrix.
This study evaluates the therapeutic application of DPSCs and L-PRF in OA via immunomodulation
and cartilage regeneration. Chondrogenic differentiation of DPSCs, with or without L-PRF exudate
(ex) and conditioned medium (CM), and of bone marrow-mesenchymal stem cells was compared.
These cells showed differential chondrogenesis. L-PRF was unable to increase cartilage-associated
components. Immature murine articular chondrocytes (iMACs) were cultured with L-PRF ex,
L-PRF CM, or DPSC CM. L-PRF CM had pro-survival and proliferative effects on unstimulated and
cytokine-stimulated iMACs. L-PRF CM stimulated the release of IL-6 and PGE2, and increased
MMP-13, TIMP-1 and IL-6 mRNA levels in cytokine-stimulated iMACs. DPSC CM increased the
survival and proliferation of unstimulated iMACs. In cytokine-stimulated iMACs, DPSC CM increased
TIMP-1 gene expression, whereas it inhibited nitrite release in 3D culture. We showed promising
effects of DPSCs in an in vitro OA model, as they undergo chondrogenesis in vitro, stimulate the
survival of chondrocytes and have immunomodulatory effects.
Keywords: dental pulp stem cells; leukocyte- and platelet-rich fibrin; osteoarthritis; cartilage
regeneration; immunomodulation
1. Introduction
Articular cartilage (AC) plays key roles in the function of diarthrodial (synovial) joints [1,2].
Cartilage injuries are very common, predominantly in young and active athletes, and particularly in
the knee joint [3–5]. They are often considered as risk factors for the development of osteoarthritis
(OA) in later life, a degenerative and inflammatory condition of the synovial joint with irreversible
cartilage loss [2]. OA results in disability, particularly in elderly people and is associated with a
large socio-economic burden [6,7]. OA is more prevalent in the female population and increases with
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age [7]. In people over 60 years of age, it is estimated that 9.6% of men and 18% of women have
symptomatic OA [8]. Unfortunately, long-lasting regeneration of damaged AC remains an unmet
clinical need. Current treatment strategies aim to relieve pain and clinical signs associated with
inflammation. However, patients show no long-term improvements [9]. With the aim to restore the
damaged cartilage tissue, matrix-induced autologous chondrocyte implantation (MACI), a Food and
Drug Administration (FDA)-approved technique, has been developed [10]. However, there are several
disadvantages such as iatrogenic damage and high costs [11–13]. To overcome these problems, the use
of innovative autologous biological tissue engineering techniques using stem cells forms an area of
large interest in an attempt to achieve AC regeneration.
Previous preclinical studies focused on the use of induced pluripotent stem cells (iPSCs) and
mesenchymal stem cells (MSCs) to repair AC, demonstrating beneficial effects mediated via different
mechanisms (as previously reviewed by our group [2]). However, because of the ethical implications
regarding the usage of iPSCs and the invasive nature of bone marrow-derived MSC (BM-MSC)
isolation, an alternative cell source is of particular interest: dental pulp stem cells (DPSCs) originating
from the neural crest-derived mesenchyme residing in the dental pulp [14,15]. Since they are
isolated from extracted human third molars, DPSCs can be obtained with minimal donor site
morbidity and iatrogenic damage. DPSCs have been classified as MSCs based upon the International
Society for Cellular Therapy (ISCT) criteria [16]. Apart from the opportunity of DPSCs to provide
a cell replacement treatment, they show therapeutic potential in OA through paracrine and trophic
influences on endogenous cells. Current evidence indicates that DPSCs can be differentiated into
cartilage-producing cells [17] and secrete numerous growth factors associated with tissue repair and
immunomodulation, including vascular endothelial growth factor (VEGF), monocyte chemoattractant
protein (MCP)-1, transforming growth factor-beta (TGF-β) and tissue inhibitors of metalloproteinases
(TIMPs) [18–20]. In addition, their immunomodulatory capacity makes them strong contenders to
be used in inflammatory disorders [21], such as OA. Interestingly, intra-articular injection of DPSCs
resulted in anti-inflammatory effects in rheumatoid arthritis (RA) [22]. Co-culture of costal chondrocytes
and DPSCs combined with fibroblast growth factors (FGF)-9 showed enhanced chondrogenesis and
reduced ossification in tissue-engineered cartilage [23]. However, until now, no chondrocyte-salvaging
or -stimulating properties have been attributed to DPSCs.
In addition, different growth factors including TGF-β, basic (b) FGF, VEGF, bone morphogenetic
proteins (BMPs) and platelet derived growth factor (PDGF) have been described to have a beneficial
effect on hyaline cartilage repair [24]. Platelets are a natural reservoir of such growth factors within
the human body [25]. Platelet concentrates such as platelet-rich plasma (PRP) and leukocyte- and
platelet-rich fibrin (L-PRF), are known to produce a plethora of autologous growth factors and
cytokines [26]. In recent years, first generation platelet-rich biomaterials such as autologous PRP have
been widely studied in order to realise AC repair [27]. In vitro studies demonstrated their positive
effects on chondrocyte proliferation and deposition of cartilage matrix [28,29]. Several preclinical
animal studies revealed positive effects on cartilage repair induced by PRP [27]. In contrast to PRP,
L-PRF is a second generation platelet concentrate which can be produced rapidly by the collection of
autologous blood after one single centrifugation step and without anticoagulants [26,30]. The generated
product is a fibrin clot consisting of three components; leukocytes, platelets and a supportive fibrin
matrix [31]. Leukocytes and platelets progressively release a high concentration of cytokines and
growth factors respectively over time [31,32]. L-PRF might be applied in cartilage engineering studies
because of its supportive fibrin matrix, while the leukocytes present in L-PRF might be important
in immunomodulatory mechanisms via cytokine secretion. To date, numerous studies have mainly
investigated the cartilage regenerative potential of other platelet derivatives, such as PRP [33]. In vitro
studies of the chondrogenic potential of L-PRF are limited [34]. Some trophic and protective effects by
PRF on chondrocytes have previously been demonstrated [35–37], and one in vitro study showed the
chondro-inductive effect of the eluate from fibrin-rich plasma membrane on a stem cell population [38].
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Because of the chondrogenic differentiation potential and immunomodulatory properties of
DPSCs, and the growth factor-rich content of L-PRF, we hypothesise that DPSCs and L-PRF can both
enhance cartilage regeneration in vitro and have immunomodulatory effects. In the current study,
first, we investigated the in vitro chondrogenic differentiation potential of human DPSCs compared to
human BM-MSCs. Second, we evaluated whether L-PRF stimulated the chondro-induction of both
MSC types in a three-dimensional (3D) cell-culture system. Third, we assessed the effect of growth factor
release of DPSCs and L-PRF on healthy chondrocytes and tumour necrosis factor-alpha (TNF-α) and
interleukin-1beta (IL-1β)-stimulated chondrocytes in vitro, on viability, OA-related gene expression,
cartilage-specific extracellular matrix (ECM) deposition and inflammatory cytokine secretion.
2. Materials and Methods
2.1. Human Stem Cell Isolation and Culture
Human third molars were obtained with written informed consent from patients (n = 16) of both
genders (15–20 years of age) undergoing an extraction procedure for orthodontic reasons at Ziekenhuis
Oost-Limburg (ZOL, Genk, Belgium). Written informed consent of minor patients was acquired via
their custodians. The study was conducted in accordance with the Declaration of Helsinki, and the
study protocol was approved by the medical ethical committee of Hasselt University (Belgium, protocol
13/0104U, date of approval 3 February 2014). The pulp tissue was obtained by means of forceps after
mechanically fracturing the teeth. Next, the pulp tissues were minced into small pieces (1–2 mm3) and
DPSCs were isolated via the explant method [17]. Cells were maintained in minimal essential medium,
alpha modification (αMEM, Sigma-Aldrich, St. Louis, MO, USA) supplemented with 100 U/mL
Penicillin and 100 µg/mL Streptomycin (Sigma-Aldrich), 2 mM l-glutamine (Sigma-Aldrich) containing
10% heat-inactivated foetal bovine serum (FBS) (Biowest, Nuaillé, France).
BM-MSCs of three different donors (both male and female), between 6 and 12 years old, were kindly
provided by Prof. Dr. Cathérine Verfaillie (Stem Cell Institute, KU Leuven, Leuven, Belgium). BM-MSCs
were kept in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich) supplemented
with 100 U/mL Penicillin and 100 µg/mL Streptomycin containing 10% heat-inactivated FBS.
All stem cells were routinely screened in our lab for the expression of the following markers:
CD34 (negative), CD44, CD45 (negative), CD90, CD105 and Stro-1 (negative) [17]. All cell cultures were
maintained at 37 ◦C in a humidified atmosphere containing 5% CO2. The culture medium was changed
every 2–3 days and all cultures were regularly monitored with an inverted phase-contrast microscope
Nikon Eclipse TS100 (Nikon Co., Shinjuku, Tokyo, Japan) equipped with a Jenoptik ProgRes C3 camera
(Jenoptik, Jena, Germany) with corresponding ProgRes Capture Pro 2.7 software. When reaching
80–90% confluence, cells were harvested using 0.05% trypsin/EDTA (Sigma-Aldrich) and sub-cultured
for further experiments. All experiments were conducted with DPSCs between passages 2 and 8.
2.2. Isolation and Culture of Immature Murine Articular Chondrocytes
Immature murine articular chondrocytes (iMACs) were isolated based upon a previously published
protocol by Gosset et al. [39] and according to the animal welfare guidelines of the ethical committee of
Hasselt University (ID 201762K, date of approval 11 November 2017). In short, after euthanasia of
5–6-day-old C57BL/6 wild type mice (n = 219), femoral heads, femoral condyles and tibial plateaus were
isolated from the hind limbs and placed in phosphate buffered saline (PBS, Lonza, Basel, Switzerland).
Isolated cartilage pieces were then incubated twice in 3 mg/mL collagenase D (Sigma-Aldrich) in low
glucose DMEM (Sigma-Aldrich) supplemented with 50 U/mL Penicillin, 50 µg/mL Streptomycin and
2 mM l-glutamine for 45 min at 37 ◦C in 5% CO2. Cartilage pieces were then incubated 0.5 mg/mL
collagenase D in standard culture medium overnight at 37 ◦C in 5% CO2. Afterwards, cartilage
fragments were passed through 25 mL, 10 mL, 5 mL and 2 mL pipettes to disperse any cell aggregates.
After passing through a 70-µm cell strainer, the cells were centrifuged at 400× g for 10 min. Cells were
resuspended in iMAC standard culture medium supplemented with 10 % heat-inactivated FBS.
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Phenotypic characterization was performed by means of immunocytochemistry (ICC) and
histological staining. In short, 26.32 × 103 cells/cm2 were seeded on glass or plastic (Thermanox®;
Electron Microscopy Sciences, Hatfield, PA, USA) cover slips for 96 h in standard culture medium
supplemented with 10% FBS. Afterwards, they were fixed using 4% paraformaldehyde (PFA) for
20 min for ICC or using 2% glutaraldehyde in 0.05 M cacodylate buffer (pH 7.3) at 4 ◦C for transmission
electron microscopy (TEM) processing. Immune-reactivity for collagen type II was demonstrated by
ICC. Culture purity was assessed by determining the fraction of collagen type 2-positive cells using
ImageJ software (The National Institute of Health, MD, USA). The presence of proteoglycans (PGs) was
demonstrated via alcian blue, toluidine blue and safranin O staining. All experiments were performed
with freshly isolated iMACs.
2.3. L-PRF Isolation
Blood samples were obtained from 11 healthy donors from both genders (aged 23–37) (n = 11)
with written informed consent. The study protocol and consent procedure were approved by the
medical ethical committee from Hasselt University and the Clinical Trial Centre from KU Leuven
(S58789/B322201628215, date of approval 21 March 2016). All experiments were performed in
accordance with relevant guidelines and regulations. Blood samples were drawn by venipuncture
and collected in glass-coated plastic tubes (VACUETTE 9 mL Z Serum Clot Activator Tubes, Greiner
Bio-One, Vilvoorde, Belgium). Samples were immediately centrifuged for 12 min at 2700 rpm (400× g)
(IntraSpin™ Centrifuge, Intra-Lock, Boca Raton, FL, USA). The L-PRF clots were removed from the
tubes using sterile forceps and separated from the red blood cell phase with an iris spatula (Fine Science
Tools, Heidelberg, Germany).
2.4. L-PRF Conditioned Medium and Exudate
For the production of L-PRF conditioned medium (L-PRF CM), L-PRF clots were placed in
6 mL of serum-free low glucose DMEM or DMEM/F12 (Thermo Fisher Scientific, Erembodegem,
Belgium) supplemented with 2 mM L-glutamine, 50 or 100 U/mL Penicillin and 50 or 100 µg/mL
Streptomycin. After 96 h, the medium was collected, centrifuged for 6 min at 300× g, sterile filtered
(0.2 µm, Sarstedt, Nümbrecht, Germany) and stored at −80 ◦C until further use. For L-PRF exudate
(L-PRF ex) collection, the L-PRF clots were brought to a sterile box (Xpression™ Fabrication Box,
Intra-Lock) and compressed, thereby releasing the exudate, which was collected, sterile filtered and
stored at −80 ◦C until further usage.
2.5. Chondrogenic Differentiation
Chondrogenic differentiation of DPSCs and BM-MSCs was induced according to the
manufacturer’s instructions (StemXVivo Human/Mouse Chondrogenic Supplement, R&D systems,
BioTechne, Minneapolis, MN, USA). A pellet containing 2.5 × 105 cells in a 15 mL conical tube
was subjected to chondrogenic differentiation medium consisting of DMEM/F12 supplemented with
1% insulin transferrin selenite (R&D systems) and 1% chondrogenic supplement (R&D systems).
This supplement consists of dexamethasone, ascorbate-phosphate, proline, pyruvate and TGF-β3 with
concentrations determined and validated by the manufacturer. To determine the effect of L-PRF on
the chondrogenic differentiation, L-PRF ex (3%) and L-PRF CM (5% and 25%) were added to the
differentiation medium. Positive and negative controls contained standard differentiation medium
with or without the chondrogenic supplement respectively. Every 2–3 days, the medium was changed.
The cells were allowed to differentiate for 21 days, after which the pellets were either fixed with 4%
PFA for immunohistochemical (IHC) analysis or with 2% glutaraldehyde in 0.05 M cacodylate buffer
(pH 7.3) at 4 ◦C for TEM processing. Percentage alcian blue and aggrecan stained area was quantified
using Image J (The National Institute of Health, MD, USA).
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2.6. DPSC Conditioned Medium
Conditioned medium of DPSCs (DPSC CM) was prepared by seeding human DPSCs at a density
of 20 × 103 cells/cm2 in standard culture medium supplemented with 10% FBS. Cells were allowed
to attach overnight. Afterwards, cells were rinsed twice with PBS and 1 mL/5 cm2 iMAC serum-free
standard culturing medium was added. 48 h later, the medium was collected, centrifuged at 161× g for
6 min and stored at −80 ◦C.
2.7. Cell Survival and Proliferation Assay
iMACs were seeded in triplicate in flat bottom 96 well plates at a density of 19.69 × 103; cells/cm2
or 29.41 × 103 cells/cm2 for survival and proliferation assays respectively and were allowed to
attach overnight. Hereafter, cells were washed twice with PBS and culture medium supplemented
with L-PRF ex (1%, 3%, 5%), L-PRF CM (5%, 25%, 50%), or DPSC CM was added. For survival
assays, the cells were cultured in serum-free conditions. For proliferation assays, experimental
conditions were supplemented with 2% FBS. Negative and positive controls consisted of iMACs
cultured in serum-deprived medium (0% or 2% for survival and proliferation respectively) or medium
supplemented with 10% FBS respectively.
For cytokine-stimulated iMACs, cells were seeded at a density of 29.41 × 103 cells/cm2 and were
allowed to adhere overnight. Subsequently, cells were washed twice with PBS and stimulated with
the inflammatory cytokines recombinant mouse TNF-α (10 ng/mL) and recombinant mouse IL-1β
(10 ng/mL) (Immunotools, Friesoythe, Germany) for 24 h. Hereafter, experimental conditions were
added, including inflammatory cytokines TNF-α and IL-1β (10 ng/mL). Unstimulated conditions
received no cytokines.
The effect of L-PRF ex, L-PRF CM and DPSC CM on iMAC viability was evaluated using propidium
iodide (PI, Sigma-Aldrich). After 24, 48, or 72 h, cells were lysed using Reagent A100 (Chemometec,
Lillerød, Denmark). Next, cells were incubated with PI (diluted 1/50 in Reagent B (Chemometec)) for
15 min in the dark. Solutions were transferred to a black 96-well plate with clear bottom (Greiner
bio-one) and fluorescence intensity was measured at an excitation wavelength of 540 nm and an
emission wavelength of 612 nm (FLUOstar OPTIMA, BMG Labtech, Ortenberg, Germany).
2.8. Reverse Transcriptase Quantitative Polymerase Chain Reaction
iMACs were seeded at a cell density of 52.63 × 103 cells/cm2 and left to adhere overnight. The cells
were subsequently washed twice with PBS and stimulated with inflammatory cytokines recombinant
mouse TNF-α (10 ng/mL) and recombinant mouse IL-1β (10 ng/mL) for 24 h. Afterwards, experimental
conditions were added containing TNF-α and IL-1β (10 ng/mL). Unstimulated conditions received no
cytokines. All cells were cultured in 2% FBS.
After 24 h, medium was collected, centrifuged and stored at −80 ◦C for enzyme-linked
immunosorbent assay (ELISA) experiments, while RNA was extracted from total cell lysates using the
RNeasy Mini Kit (74104, Qiagen, Venlo, the Netherlands) according to the manufacturer’s instructions.
After reverse transcription to cDNA using qScript cDNA Supermix (Quanta Bioscience, Carlsbad, CA,
USA), a quantitative PCR was conducted on a StepOnePlus detection system (Applied Biosystems,
Foster City, CA, USA) using standardised cycling conditions (20 s at 95 ◦C, 40 cycles of 3 s at 95 ◦C and
30 s at 60 ◦C). Primer sequences are listed in Supplementary Table S1.
2.9. Enzyme-Linked Immunosorbent Assay
ELISAs were performed for IL-6 and prostaglandin E2 (PGE2) (R&D systems). ELISAs were
performed according to the guidelines of the manufacturer. The absorbance of the end product was
measured with a plate reader (FLUOstar OPTIMA and iMARK Microplate Reader, Biorad, Temse,
Belgium). To ensure that the measured concentrations in L-PRF ex, L-PRF CM and DPSC CM were
iMAC-derived, the conditions were included in the ELISA experiment as a control.
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2.10. Nitrite Measurements
iMACs were seeded at a density of 52.63 × 103 cells/cm2 and were allowed to adhere for 24 h. Cells
were subsequently washed twice met PBS and stimulated with the inflammatory cytokines TNF-α
(10 ng/mL) and IL-1β (10 ng/mL). After 24 h, experimental conditions were added containing TNF-α
and IL-1β (10 ng/mL). Unstimulated conditions received no cytokines. All cells were cultured in 2%
FBS. After another 24 h, the medium was collected, centrifuged and stored at −80 ◦C.
Nitrite was quantified using the Griess Reagent System (Promega Benelux B.V., Leiden,
The Netherlands) according to the manufacturer’s guidelines. Absorbance was measured at a
wavelength of 540 nm using a plate reader (FLUOstar OPTIMA).
2.11. Three-Dimensional Culture of iMACs
For cytokine-stimulated iMAC pellets, 5 × 105 iMACs were washed twice and resuspended in
culture medium containing recombinant mouse TNF-α (10 ng/mL) and recombinant mouse IL-1β
(10 ng/mL). Cells were centrifuged in 15 mL polypropylene tubes at 400× g and maintained at 37 ◦C
under 5% CO2. The caps of the tubes were loosened to allow for air exchange. 24 h later, the medium was
replaced for the experimental conditions with TNF-α and IL-1β (10 ng/mL). Unstimulated conditions
received no cytokines. All conditions were cultured in 2% FBS. 72 h later, the medium was collected,
centrifuged and stored at −80 ◦C for nitrite measurements, while pellets were fixed with 4% PFA
for IHC.
2.12. Immunocytochemical Staining
For collagen type II expression in iMACs, permeabilisation and blocking occurred simultaneously
with 10% protein block (DAKO, Glostrup, Denmark) and 0.2% Triton in PBS for one hour. Cells were
then incubated with an anti-collagen type II antibody (ab34712, polyclonal, 1:100, Abcam, Cambridge,
UK) diluted in 10% protein block in PBS for one hour at room temperature (RT). Afterwards, they were
incubated with the Alexa 555-labelled donkey anti-rabbit IgG (A31572, Thermo Fisher Scientific) diluted
1/500 in PBS for 30 min. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, Thermo
Fisher Scientific) for 10 min. Samples were mounted using fluorescence mounting medium (DAKO).
Pictures were taken with a Leica DM4000 B Microscope (Leica Microsystems, Wetzlar, Germany).
2.13. (Immuno)histology
2.13.1. Immunohistochemistry
Cartilage pellets were embedded in paraffin and 7 µm thick sections were cut. Samples were
deparaffinised in xylene and ethanol baths (xylene: 2 times 5 min, ethanol: 100%, 100%, 95%, 80%,
70%, 50%, 2 min each). Antigen retrieval was performed by heating the samples three times for
5 min in 1× target retrieval solution (DAKO). In case of 3,3’-Diaminobenzidine (DAB, DAKO) staining,
peroxidase block (DAKO) was used for 20 min. Next, nonspecific binding of the antibodies was inhibited
with protein block (DAKO) for 30 min at RT. Samples were then incubated with an anti-aggrecan
antibody (ab186414, clone number EPR14664, 1:500, Abcam) diluted in 10% protein block in PBS for
one hour at RT. Subsequently, samples were incubated with the advance HRP Link System (K4067,
DAKO) for 30 min at RT. Hereafter, samples were incubated with DAB for 5 min and counterstained
with haematoxylin for 8 min after which they were washed with running tap water for 20 min.
2.13.2. Histology
For histological analyses routinely used safranin O, alcian blue, toluidine blue and Masson’s
trichrome staining were performed (See Supplemental Materials and Methods).
All samples were dehydrated in ethanol and xylene (ethanol: 70%, 80%, 95%, 100%, 100%, 100%
xylene, 100% xylene, 2 min each) and mounted using DPX (Merck, Darmstadt, Germany). Slides were
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visualised with the Mirax slide scanner (Carl Zeiss NV-SA, Zaventem, Belgium) using the Mirax scan
software. Photos of scanned slides were made with the Mirax viewer (Carl Zeiss NV-SA) or images
were taken with a Leica DM2000 LED Microscope.
2.14. Transmission Electron Microscopy
Samples were processed for TEM imaging as described previously [40]. After fixation, the fixative
was aspirated with a glass pipette, and samples were postfixed in 2% osmium tetroxide for one
hour. Subsequently, samples were placed through a dehydrating series of graded concentrations of
acetone. Dehydrated samples were impregnated overnight in a 1:1 mixture of acetone and araldite
epoxy resin at RT. After impregnation, samples were embedded in araldite epoxy resin at 60 ◦C and
monolayer samples were embedded in araldite according to the popoff method [41]. Ultrathin sections
(0.06 µm) were mounted on 0.7% formvar-coated copper grids (Aurion, Wageningen, the Netherlands),
contrasted with 0.5% uranyl acetate and a stabilised solution of lead citrate using a Leica EM AC20
(Leica). Samples were observed using a Philips EM 208 transmission electron microscope (Philips,
Eindhoven, The Netherlands) equipped with a Morada Soft Imaging System camera with corresponding
iTEM-FEI software (Olympus SIS, Münster, Germany).
2.15. Statistical Analysis
Statistical analysis was performed using Graphpad Prism 7.04 software (Graphpad, San Diego,
CA, USA). Normality was tested using the Shapiro-Wilk and the D’Agostino and Pearson normality
test. Normal distributed data were tested with one-way analysis of variance (ANOVA) or two-way
ANOVA and Dunnet’s multiple comparison post-test. Nonparametric data were analysed with the
Kruskal-Wallis test followed by Dunn’s post-test. Any p-value ≤ 0.05 was considered to be statistically
significant. All data were presented as mean ± standard error of mean (S.E.M.).
3. Results
3.1. Differences in Chondrogenic Differentiation Potential Between BM-MSCs and DPSCs and the Effect of
Exposure to L-PRF During Chondrogenesis
In order to compare the chondrogenic differentiation potential between human DPSCs and
BM-MSCs, cells were subjected to a 3D chondrogenic differentiation system over 21 days. To test
the effect of exposure to L-PRF during chondrogenic differentiation, cells were subjected to the same
3D differentiation system, but supplemented with L-PRF ex (3%) or L-PRF CM (5% and 25%) for
21 days (n = 3). Following the three week culture, both cell types formed compact 3D micromasses
under all experimental conditions (Figure 1A). IHC revealed abundantly present ECM surrounding
both differentiated stem cell types (Figure 1A). Ultrastructural analyses of the 3D micropellets of
both cell types showed the presence of dense matrix-filled vesicles, suggesting glycosaminoglycan
(GAG) production (Figure 1B, arrowheads). This was supported by the alcian blue staining which
demonstrated the presence of GAGs in the ECM of both differentiated MSC types (Figure 1C).
Quantitative analysis of GAG production demonstrated no significant difference between DPSCs and
BM-MSCs after 21 days of differentiation (Figure 1D). Moreover, when the chondrogenic differentiation
medium was supplemented with L-PRF ex or L-PRF CM, the percentage of the alcian blue-stained
area in micropellets derived from both cell types was not significantly different (Figure 1D). Aggrecan
expression could only be detected in differentiated BM-MSCs and remained absent in DPSC-derived
pellets (Figure 1E,F). Exposure to L-PRF ex or CM did not significantly augment the aggrecan expression
in cartilage spheres derived from BM-MSCs (Figure 1F). The control pellet resulted in 36.69% ± 10.89%
aggrecan-positive stained area, while 5% L-PRF CM caused 27.24% ± 16.22% aggrecan-positive area
compared to 21.34% ± 4.61% aggrecan-stained area in BM-MSCs supplemented with 25% L-PRF CM.
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Figure 1. Differences in chondrogenic differentiation potential between human dental pulp stem cells 
(DPSCs) and human bone marrow-derived MSCs (BM-MSCs) and the effect of exposure to L-PRF 
during chondrogenesis. After 21 days of exposure to L-PRF ex (3%) or L-PRF conditioned medium 
(CM) (5% and 25%), cartilage-specific protein expression in differentiated pellets was evaluated using 
(immuno)histological staining (n = 3). (A) Masson’s trichrome staining revealed the presence of 
abundant extracellular matrix (ECM) in micropellets derived from both differentiated stem cell types. 
(B) Ultrastructural analyses of the micropellets of both cell types showed the presence of dense 
matrix-filled vesicles (arrowheads). (C) Glycosaminoglycan (GAG) production was assessed by 
means of alcian blue staining. (D) L-PRF ex or L-PRF CM stimulation did not enhance the GAG area 
percentage. (E) Immunohistochemical (IHC) revealed that aggrecan expression was present in 
differentiated BM-MSCs, but absent in the DPSC-derived pellets. (F) Aggrecan area percentage was 
not enhanced by L-PRF ex or L-PRF CM exposure. Scale bars A, C, E = 100 μm; B = 2 μm. Data in D 
and F are represented as mean ± S.E.M. 
3.2. Phenotypical and Ultrastructural Characterization of Immature Murine Articular Chondrocytes  
iMACs were isolated from the femoral heads, femoral condyles and tibial plateau from hind 
limbs of 5–6-day-old wild type C57BL/6 mice. Phase contrast images revealed a rounded and 
polygonal morphology with a granular cytoplasm (Figure 2A). Expression of the main markers of 
chondrocyte phenotype was assessed via (immuno)histology. Alcian blue and toluidine blue staining 
show the presence of PG components (Figure 2B, C), while ICC demonstrated collagen type II 
expression by iMACs (Figure 2D). The average culture purity was 93.24% ± 1.33% (n = 3). Together, 
iMACs synthesise type II collagen and sulphated PGs in vitro after 4 days, showing the isolation of 
functional chondrocytes. Ultrastructurally, chondrocytes were characterised by a rounded, spherical 
morphology with ample rough endoplasmic reticulum, mitochondria and glycogen-rich vacuoles 
(Figure 2E and insert).  
3.3. Effect of Secreted Factors of DPSCs and L-PRF on Healthy Chondrocyte Survival and Proliferation and 
Viability of TNF-α- and IL-1β-Stimulated iMACs  
Figure 1. Differences in chondrogenic differentiation potential between human dental pulp stem
cells (DPSCs) and human bone marrow-derived MSCs (BM-MSCs) and the effect of exposure to
L-PRF during chondrogenesis. After 21 days of exposure to L-PRF ex (3%) or L-PRF conditioned
medium (CM) (5% and 25%), cartilage-specific protein expression in differentiated pellets was evaluated
using (immuno)histological staining (n = 3). (A) Masson’s trichrome staining revealed the presence
of abundant extracellular matrix (ECM) in micropellets derived from both differentiated stem cell
types. (B) Ultrastructural analyses of the micropellets of both cell types showed the presence of
dense matrix-filled vesicles (arrowheads). (C) Glycosaminoglycan (GAG) production was assessed
by means of alcian blue staining. (D) L-PRF ex or L-PRF CM stimulation did not enhance the GAG
area percentage. (E) Immunohistochemical (IHC) revealed that aggrecan expression was present in
differentiated BM-MSCs, but absent in the DPSC-derived pellets. (F) Aggrecan area percentage was not
enhanced by L-PRF ex or L-PRF CM exposure. Scale bars A, C, E = 100 µm; B = 2 µm. Data in D and F
are represented as mean ± S.E.M.
3.2. Phenotypical and Ultrastructural Characterization of Immature Murine Articular Chondrocytes
iMACs were isolated from the femoral heads, femoral condyles and tibial plateau from hind limbs
of 5–6-day-old wild type C57BL/6 mice. Phase contrast images revealed a rounded and polygonal
morphology with a granular cytoplasm (Figure 2A). Expression of the main markers of chondrocyte
phenotype was assessed via (immuno)histology. Alcian blue and toluidine blue staining show the
presence of PG components (Figure 2B,C), while ICC demonstrated collagen type II expression by
iMACs (Figure 2D). The average culture purity was 93.24% ± 1.33% (n = 3). Together, iMACs synthesise
type II collagen and sulphated PGs in vitro after 4 days, showing the isolation of functional chondrocytes.
Ultrastructurally, chondrocytes were characterised by a rounded, spherical morphology with ample
rough endoplasmic reticulum, mitochondria and glycogen-rich vacuoles (Figure 2E and insert).
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Figure 2. Phenotypic characterization of immature murine articular chondrocytes (iMACs) and the
effect of L-PRF ex, L-PRF CM and DPSC CM on iMAC survival, proliferation and chondrocyte viability
in TNF-α- and IL-1β-stimulated conditions. (A) Phase contrast micrographs of mouse iMACs show a
rounded, polygonal morphology. (B–D) Histological staining revealed the production of sulphated
PGs, while immunofluorescence staining demonstrated collagen type II expression. (E) Transmission
electron microscopy (TEM) showed a rounded, spherical morphology with abundant rough endoplasmic
reticulum, mitochondria and glycogen-rich (GL) vacuoles (insert). The effect of the secretome of L-PRF
and DPSCs on unstimulated iMAC survival, proliferation and cytokine-stimulated iMAC viability were
evaluated by means of a PI assay (F–K). (F) 25% and 50% L-PRF CM had a significant pro-survival effect
on iMACs after 24 h compared to the negative control (n = 5). (G) 5%, 25% and 50% L-PRF CM had a
significant proliferative effect on iMACs after 48 h and 72 h compared to the negative control (n = 4).
(H) 25% and 50% L-PRF CM significantly increased the viability of TNF-α- and IL-1β-stimulated
iMACs after 48 h and 72 h (n = 5 for 24 h, n = 6 for 48 h, n = 6 for 72 h). (I) DPSC CM had a significant
pro-survival effect on iMACs after 24 h compared to the negative control (n = 8). (J) DPSC CM
significantly increased the proliferation of iMACs after 48 h and 72 h (n = 7 for 24 h, n = 8 for 48 h,
n = 9 for 72 h). (K) TNF-α- and IL-1β-stimulated iMAC viability follows an increasing trend after
exposure to DPSC CM, although not statistically significant. (n = 8 for 24 h, n = 10 for 48 h, n = 8 for
72 h). Scale bars A, B, C and D = 50 µm. Scale bar E: 5 µm (original magnification: 5,600). Data are
represented as mean ± S.E.M. * p ≤ 0.05. ** p ≤ 0.01. *** p ≤ 0.001. **** p ≤ 0.0001.
3.3. Effect of Secreted Factors of DPSCs and L-PRF on Healthy Chondrocyte Survival and Proliferation and
Viability of TNF-α- and IL-1β-Stimulated iMACs
In order to evaluate the influence of L-PRF ex, L-PRF CM and DPSC CM on the viability
of unstimulated or cytokine-stimulated iMACs, a PI test was employed at different time points
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(Figure 2F–K). After 24 h, serum deprivation decreased survival compared to iMACs cultured in
high serum conditions (Figure 2F,I). This effect could not be prevented by supplementation of L-PRF
ex to iMACs (Figure 2F). In contrast, the highest L-PRF CM concentrations (25% and 50%) had a
significant pro-survival effect compared to the negative control condition and this was demonstrated
to have a proliferative influence when serum was absent (139% ± 11.93% for 25% L-PRF CM and
120.2% ± 3.02% for 50% L-PRF CM) (Figure 2F). When 2% serum was supplemented, all L-PRF
CM concentrations (5%, 25% and 50%) significantly increased iMAC proliferation at 48 h and 72 h
(Figure 2G). When iMACs were stimulated with TNF-α and IL-1β, 25% and 50% L-PRF CM showed a
statistically significant increased viability compared to the cytokine-stimulated negative control at 48 h
and 72 h (177% ± 39.51% and 183.7% ± 38.24% for 25% and 50% L-PRF CM respectively compared
to 65.1% ± 17.4% for the stimulated negative control for 48 h, 196.4% ± 33.86% and 231.2% ± 45.66%
for 25% and 50% L-PRF CM respectively compared to 53.41% ± 26.7% for the stimulated negative
control at 72 h) (Figure 2H). L-PRF ex did not exert any stimulating effects on proliferation or viability
of neither unstimulated nor cytokine-stimulated iMACs. In serum-deficient conditions, DPSC CM
significantly stimulated iMAC survival compared to the negative control (84.16% ± 12.06% compared
to 49.08% ± 11.81%) after 24 h (Figure 2I). In 2% serum conditions, iMAC underwent a significant
increased proliferation compared to the negative control after 48 h and 72 h when cultured in DPSC CM
(Figure 2J). When cytokine-stimulation was implemented, iMAC viability followed an increasing trend
when cultured in DPSC CM at every time point, although this effect was not significant (Figure 2K).
3.4. Effect of Secreted Factors of DPSCs and L-PRF on OA-related mRNA Expression of Unstimulated and
TNF-α- and IL-1β-Stimulated iMACs
Expression levels of chondrocyte-markers were investigated in unstimulated iMACs cultured
with 3% L-PRF ex, 25% L-PRF CM and DPSC CM after 24 h (Figure S1). Aggrecan mRNA levels
were significantly decreased upon supplementation of 3% L-PRF ex and 25% L-PRF CM (Figure S1A).
25% L-PRF CM significantly decreased mRNA levels of collagen type II α 1 (Figure S1B). TGF-β
mRNA levels were not significantly altered by L-PRF ex, L-PRF CM and DPSC CM (Figure S1C).
Matrix metalloproteinase (MMP)-13 was significantly upregulated in iMACs cultured with 25% L-PRF
CM compared to control (Figure S1D), while TIMP-1 mRNA expression levels were significantly
upregulated by the supplementation of 25% L-PRF CM and DPSC CM (Figure S1E).
After iMACs were cytokine stimulated for 24 h and cultured in experimental conditions for
another 24 h, gene expression levels of OA-related markers aggrecan, collagen type II α 1, TGF-β,
MMP-13, TIMP-1, a disintegrin and metalloproteinase (ADAM)-17, IL-6, TNF-α and inducible nitric
oxide synthase (iNOS) were measured. As shown in Figure 3, reverse transcriptase quantitative
polymerase chain reaction (RT-qPCR) results showed that cytokine stimulation of iMACs significantly
decreased cartilage-specific mRNA levels, such as aggrecan and collagen type II α 1, compared to
unstimulated iMACs after 24 h (Figure 3A,B). No significant increase in aggrecan or collagen type
II α 1 could be observed when iMACs were cultured with 3% L-PRF ex, 25% L-PRF CM or DPSC
CM (Figure 3A,B). mRNA levels of TGF-β, a growth factor playing indispensable roles in cartilage
integrity and homeostasis, were also measured using RT-qPCR and were not significantly altered
(Figure 3C). TNF-α and IL-1β stimulation of iMACs increased mRNA levels of the chondrocyte
maturation marker MMP-13 compared to unstimulated iMACs (Figure 3D). Moreover, 25% L-PRF CM
significantly increased MMP-13 mRNA levels (Figure 3D), while TIMP-1 was significantly upregulated
by the supplementation of pro-inflammatory cytokines combined with 25% L-PRF CM and DPSC CM
compared to the stimulated control after 24 h (Figure 3E). ADAM-17 mRNA levels were significantly
increased upon exposure to cytokines, but not altered by the supplementation of L-PRF ex, L-PRF CM
or DPSC CM (Figure 3F). Cytokines with 25% L-PRF CM significantly amplified the IL-6 mRNA levels
compared to the stimulated control (Figure 3G). TNF-α and iNOS mRNA levels were significantly
increased upon exposure to cytokines, and are not altered upon supplementation of L-PRF ex, L-PRF
CM or DPSC CM (Figure 3H,I).
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after 24 h and subjected to an ELISA for IL-6 and PGE2 (Figure 4). Cytokine stimulation enhanced IL-
6 production by iMACs, although not significantly, from 0 ng/mL for the unstimulated control to 6.31 
ng/ml ± 1.65 ng/mL for the stimulated control (Figure 4A). Of all experimental conditions, only 25% 
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Figure 3. Effect of L-PRF ex, L-PRF CM and DPSC CM on TNF-α- and IL-1β- stimulated iMAC
OA-related gene expression. Relative mRNA levels were determined by RT-qPCR of unstimulated and
cytokine-stimulated iMACs exposed to 3% L-PRF ex, 25% L-PRF CM and DPSC CM. (A,B) Chondrocyte
marker genes, aggrecan and collagen type II α 1, were significantly downregulated by cytokine stimulation,
but not significantly altered by L-PRF ex, L-PRF CM and DPSC CM. (C) TGF-β mRNA levels were
not altered upon exposure to cytokines, nor in combination with L-PRF ex, L-PRF CM or DPSC CM.
(D) MMP-13 was significantly upregulated after cytokine stimulation, while 25% L-PRF CM further
increased MMP-13 mRNA levels compared to the stimulated control. (E) TIMP-1 was upregulated
by the supplementation of pro-inflammatory cytokines combined with 25% L-PRF CM and DPSC
CM. (F) ADAM-17 expression was significantly upregulated after cytokine stimulation but not altered
after exposure to L-PRF ex, L-PRF CM and DPSC CM. (G) 25% L-PRF CM significantly augmented
the IL-6 mRNA levels compared to the stimulated control. (H,I) TNF-α and iNOS mRNA levels were
upregulated upon exposure to cytokines, but not altered by the supplementation of L-PRF ex, L-PRF
CM or DPSC CM. Data correspond to n = 6 for L-PRF ex and L-PRF CM and n = 7 for DPSC CM. Data
are represented as mean ± S.E.M. * p ≤ 0.05. ** p ≤ 0.01. *** p ≤ 0.001. **** p ≤ 0.0001.
3.5. IL-6 and PGE2 Release Are Increased After Supplementation of Cytokines Combined With L-PRF CM
The medium of iMACs cultured in 3% L-PRF ex and 25% L-PRF CM and DPSC CM was collected
after 24 h and subjected to an ELISA for IL-6 and PGE2 (Figure 4). ytokine stimulation enhanc
IL-6 production by iMACs, although not sig ificantly, from 0 ng/mL for the unstimulated ontrol
to 6.31 ng/mL ± 1.65 ng/mL for t e s imulated cont l (Figure 4A). Of all experim ntal conditions,
only 25% L-PRF CM significantly enhanced IL-6 secretion (Figure 4A). Stimulation with cytokines
in combination w th 25% L-PRF CM induced a significant increase in PGE2 release by MACs
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(86 ng/mL ± 24.14 ng/mL for stimulated 25% L-PRF CM compared to 2.75 ng/mL ± 1.11 ng/mL for the
stimulated control) (Figure 4B).
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Figure 4. IL-6 and PGE2 secretion of iMACs after exposure to inflammatory cytokines and L-PRF ex,
L-PRF CM and DPSC CM, measured via ELISA. (A) IL-6 release of iMACs is significantly increased
after exposure to cytokine stimulation combined with 25% L-PRF CM. (B) Stimulation with cytokines
in combination wi h 25% L-PRF CM induc a significant increase in PGE2 release by iMAC .
Data correspo d to n = 3. Data are represented as mean ± S.E.M. ** p ≤ 0.01. *** p ≤ 0.001.
3.6. Nitrite Levels Are Increased Upon Cytokine Stimulation and Decreased by DPSC CM
To evaluate the influence of secreted factors of L-PRF and DPSCs on iMAC nitrite secretion,
a Griess assay was performed. iMACs secreted significant more nitrite when they were stimulated
with TNF-α and IL-1β in monolayer and 3D pellet culture (Figure 5A,B). In monolayer, 25% L-PRF
CM exerted a small decrease in the nitrite secretion from 30.09 µM ± 1.69 µM to 26.69 µM ± 1.13 µM
(Figure 5A). However, this effect was not significant. Also in pellet culture, L-PRF CM exerted a small
not significant decrease in nitrite release by cytokine-stimulated iMACs. L-PRF ex did not decrease the
nitrite secretion in cytokine-stimulated iMAC after 24 h in monolayer, nor after 72 h in pellet culture.
CM of DPSCs induced a small, but not significant reduction in nitrite production of iMACs after 24 h
from 30.09 µM ± 1.69 µM to 26.33 µM ± 1.84 µM in monolayer (Figure 5A). Remarkably, DPSC CM
significantly decreased nitrite secretion of iMACs in micromass culture from 30.25 µM ± 1.87 µM to
17.08 µM ± 2.42 µM (Figure 5B).
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Figure 5. The effect of L-PRF ex, L-PRF CM and DPSC CM on TNF-α and IL-1β-stimulated iMAC nitrite
release. Nitrite production in iMACs cultured in monolayer (A) and micropellet (B) was measured
via the Griess assay. (A) In monolayer culture, nitrite production was significantly increased upon
cytokine stimulation but not significantly altered by exposure to L-PRF ex, L-PRF CM and DPSC CM
after 24 h. (B) In 3D micropellets, DPSC CM significantly reduced nitrite release of iMACs after 72 h.
Data correspond to n = 5 for L-PRF ex and L-PRF CM, n = 7 for DPSC CM (A), n = 6 for L-PRF ex, n = 7
for L-PRF CM and DPSC CM (B). Data are represented as mean ± S.E.M. * p ≤ 0.05. **** p ≤ 0.0001.
3.7. Cartilage-Specific ECM Production of iMACs in 3D Culture After Exposure to L-PRF ex, L-PRF CM and
DPSC CM
To test the effect of secreted factors of L-PRF and DPSCs on the cartilage-matrix production of
cytokine-stimulated iMACs, 5 × 105 iMACs cultured in micromasses were stimulated with TNF-α
and IL-1β for 24 h. Afterwards, experimental conditions were added and 72 h later cell pellets were
used for histological examination of the cartilaginous structure. Unstimulated iMAC pellets generated
a typical cartilage-like tissue composed of chondrocytes in distinct lacunae surrounded by a dense
PG-rich matrix as shown by representative images of alcian blue, toluidine blue and safranin O staining
(Figure 6, arrowheads). However, pellets formed by cytokine-stimulated iMACs developed into a
more fibrous tissue in which cartilage-lacunae were less evident and meaningfully decreased ECM
and GAG production could be observed. This was revealed by an obvious decrease in alcian blue,
toluidine blue and safranin O staining intensity (Figure 6). Cytokine-stimulated iMACs cultured
with 3% L-PRF ex, 25% L-PRF CM and DPSC CM attained slightly more typical cartilage-like lacunae
and showed a weak tendency of improved ECM content and chondrocyte status compared to the
cytokine-stimulated control. A tendency to a higher alcian blue staining intensity could also be
observed when cytokine-stimulated iMACs were cultured on L-PRF ex, L-PRF CM and DPSC CM.
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Figure 6. TNF-α- and IL-1β-stimulated iMACs cultured in 3D pellets attenuated a more cartilage-like
morphology after exposure to L-PRF ex, L-PRF CM and DPSC CM. Representative images showed
that unstimulated iMAC pellets generated a cartilage-like tissue with large numbers of chondrocytes
present in lacunae (arrowheads). In the cytokine-stimulated control condition, iMACs developed into a
more fibrous tissue in which cartilage-lacunae were less evident and GAG production is meaningfully
reduced, as shown by an apparent decrease in alcian blue, toluidine blue and safranin O staining
intensity. Cartilage lacunae were more preserved by L-PRF ex, L-PRF CM and DPSC CM with a
weak tendency of improved ECM content and chondrocyte status compared to the stimulated control.
Data correspond to n = 3. Scale bars = 50 µm.
4. Discussion
The suggested mechanisms via which MSCs mediate cartilage repair and aid in OA include
replacement of damaged cartilage tissue and paracrine-mediated effects such as proliferation of
endogenous cells and immunomodulation [2].
In the first phase of the current study, the chondrogenic differentiation capacities of DPSCs were
compared to BM-MSCs. Both BM-MSCs and DPSCs were shown to generate compact cartilage-like
3D spheres by differentiated cells surrounded by abundant ECM and GAGs. One of the most
predominant PG, aggrecan, was not expressed in differentiated DPSCs, but cartilage spheres generated
by BM-MSCs show abundant aggrecan secretion in the ECM. The absence of aggrecan in differentiated
DPSC pellets in our study might be ascribed to several factors. One of these factors might be the
differentiation time since an improved chondrocyte phenotype is reported upon prolonged culture
times [42]. After a differentiation period of 6 weeks, aggrecan expression was reported in human
DPSCs by Mata and colleagues [43]. Another factor might be the culture settings as many utilised
scaffolds to improve the phenotype of DPSC-derived chondrocytes in vitro, including hydrogels
containing poly(ethylene glycol) dimethacrylate (PEGDMA), methacrylated gelatin (GelMA) and
hyaluronic acid (HA) [44] and chitosan-based scaffolds [45], but did not always test for aggrecan
expression. In addition to differentiation time and culture environment, also hypoxic conditions and the
addition of specific carbohydrates or growth factors might improve the expression of cartilage-specific
components [24,46,47]. Dai et al. reported that costal chondrocytes combined with exogenous FGF-9
are suitable to supply chondro-inductive stimuli to DPSCs [23]. Rizk and colleagues showed that
TGF-β3-transduced DPSCs express chondrogenic markers, including aggrecan [48]. Similar to our
data, they showed that a positive staining for aggrecan was not evident in micromasses made by
non-transduced DPSCs. Finally, the absence of aggrecan expression in our study might also have been
influenced by inter-donor variability, as for example donor age might impact MSC differentiation [49,50].
Our data demonstrated that DPSCs show competences to differentiate towards the chondrogenic
lineage, however we were not able to show aggrecan expression. Despite other reports indicate
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that DPSCs could be used for hyaline cartilage engineering studies, these cells might, for example,
be promising for engineering of fibrocartilaginous tissues such as for the temporomandibular joint
(TMJ). The latter has been demonstrated by a recent report of Longoni et al. in which they show that
under various chondro-inductive conditions DPSCs formed more fibrocartilage-like tissues instead of
hyaline cartilage [51].
Chondrogenesis of MSCs has been shown to be enhanced by the supplementation of growth
factors [24]. The beneficial properties of L-PRF have mainly been attributed to the high concentration
of platelets, leukocytes and the long-term release of growth factors by the L-PRF matrix [52].
We investigated the effect of L-PRF ex and L-PRF CM on the chondrogenic differentiation of DPSCs
and BM-MSCs. Our results show that L-PRF ex and L-PRF CM were neither able to significantly
increase the GAG secretion in both cell types nor induce aggrecan expression in DPSCs. Reports on
chondro differentiation-promoting effects of platelets aggregates, such as PRP, on MSCs are contentious.
Several previously confirmed chondro-inductive stimuli of platelet concentrates to MSCs [38,53–55],
whereas others indicate that PRP treatment does not improve the in vitro chondrogenesis of MSCs [56].
The difference between the previously identified differentiation-promoting effects of platelets aggregates
such as PRP in musculoskeletal diseases (reviewed by Qian et al. [57]), and our data on L-PRF might
be caused by different factors. First, various platelet concentrates have different release kinetics [58].
Second, compared to other platelet concentrates, L-PRF contains significantly higher concentrations of
leukocytes [59]. With reference to this, the leukocytes in L-PRF have positive effects (e.g. anti-microbial
properties [59]), but might at the same time be involved in catabolic pathways [60]. Moreover,
the leukocyte fraction in L-PRF has been reported to be accountable for the overproduction of several
growth factors, including VEGF and inflammatory cytokines [59,61], which have been described to
negatively impact chondrogenesis in vitro [31,62–67]. In contrast, many other growth factors present in
L-PRF ex and L-PRF CM are reported to have beneficial influences on MSC chondrogenesis [31,34,68,69].
To date, our data strongly indicate that the supplementation of L-PRF ex and L-PRF CM does not alter
MSC chondrogenesis in vitro.
In a second phase, the secretome-mediated effects of human DPSCs and L-PRF on (TNF-α- and
IL-1β-stimulated) iMACs were investigated. iMACs were isolated and phenotypically characterised
based upon criteria identified by Gosset et al. [39]. It is broadly documented that chondrocytes
de-differentiate to fibroblast-like cells in monolayer and can bias outcomes [39,70]. To overcome this,
all data were generated using freshly isolated chondrocytes. TNF-α- and IL-1β-stimulated chondrocytes
transformed into cells with a reduced function, such as decreased cartilage-specific matrix mRNA levels,
increased MMPs, inflammatory gene expressions and suppressed GAG production. These findings
demonstrated the establishment of robust OA-mimicked chondrocytes in vitro.
We demonstrated that L-PRF CM significantly enhanced unstimulated iMAC survival, proliferation
and TNF-α- and IL-1β-stimulated iMAC viability in a concentration-dependent manner. These effects
were not observed in iMACs cultured in the presence of L-PRF ex. In contrast to our findings, Chien et al.
demonstrated that the exudate of PRF could improve chondrocyte proliferation when cultured in
fibrin-based scaffolds [35]. This alteration in outcome between the two L-PRF derivatives might be
explained in the difference in growth factor levels. Specifically, significantly higher levels of growth
factors are found in L-PRF CM compared to L-PRF ex, which can be caused by the fact that L-PRF
CM is generated after incubation for 96 h, resulting in a continuous release of growth factors by the
leukocytes in the fibrin matrix of the L-PRF [26,31]. RT-qPCR data demonstrated at 24 h post-stimulation
a significant decrease in aggrecan and collagen type II α 1 mRNA levels of healthy iMACs when cultured
in the presence of L-PRF CM. L-PRF ex significantly decreased aggrecan mRNA expression. In addition,
MMP-13 and TIMP-1 mRNA expressions were increased in unstimulated iMACs upon 25% L-PRF
stimulation. The increased proliferative state of iMACs upon L-PRF CM supplementation seems to
be accompanied by a downregulation of cartilage-specific ECM components and the upregulation of
MMP-13 in healthy iMACs. When iMACs were cytokine-stimulated, L-PRF CM significantly increased
MMP-13, TIMP-1 and IL-6 mRNA levels. ELISA demonstrated a significant increase of IL-6 and PGE2
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secretion, two inflammatory mediators in OA by cytokine-stimulated iMACs upon exposure to 25%
L-PRF CM. IL-6 is widely known to mediate several pro-inflammatory responses contributing to the
pathogenesis of several immune-related diseases, such as RA [71]. Therefore, therapeutic targeting
IL-6 has become important in the drug development applications of these diseases. Tocilizumab
(TCZ), an IL-6 receptor-inhibiting monoclonal antibody, is widely used in the treatment of RA [72].
However, the role of IL-6 in OA remains unclear. High levels of IL-6 are found in the synovial fluid of
OA patients. These high IL-6 levels are associated with increased MMP levels and radiographic OA
changes [73,74]. Additionally, it was reported that inhibition of IL-6 with TCZ lowered pain behaviour
in an experimental model of OA in rats [75]. In contrast, IL-6 knockout mice revealed the progression
of more advanced OA than wild-type animals and injection of IL-6 in the joint of IL-6-deficient mice
reduced cartilage loss during arthritis [76,77]. Nevertheless, based on the above outcomes, our data
might indicate an inability of L-PRF to counteract cytokine-induced phenotypical changes of iMACs
in vitro.
Several growth factors, such as VEGF, EGF, IL-6 and MCP-1, are highly present in L-PRF CM and
in minor levels in the exudate [31,64] and might be accountable for the observed effects in the present
study. For example, VEGF is reported to act as a survival factor in growth plate chondrocytes and has
proliferative effects in immortalised chondrocytes [78]. Moreover, increased MMP levels and secretion
are reported because of VEGF [79,80]. Pufe and colleagues also showed pro-inflammatory factors
such as IL-1β, nitric oxide, TNF-α and IL-6 to be induced by VEGF [80]. Also EGF and IL-6 increased
numbers of chondrocytes [81,82]. Furthermore, IL-6 is described to be able to increase MMP expression
alone or in synergy with IL-1β and oncostatin M [83–85]. In addition, MCP-1 increased MMP-13
expression in chondrocytes [86]. Furthermore, several other proteins that are abundantly present in
L-PRF CM, such as RANTES, growth regulated oncogene (GRO) and IL-8 might be responsible for
the observed effects in our study [31]. RANTES is demonstrated to induce chondrocyte expression of
inducible NO synthase, IL-6 and MMP-1 [87], while IL-8 and GROα are shown to induce articular
chondrocyte hypertrophy and calcification through increased type X collagen, MMP-13 expression and
alkaline phosphatase activity [88].
In contrast to our findings, numerous other studies demonstrated that a large number of growth
factors found to be secreted by platelet derivatives have predominantly beneficial and promising
activities for (pre-)clinical applications for chondrogenesis and anti-inflammatory effects [33]. To date,
studies mainly focused on the role of platelets and platelet-derived growth factors, since these are the
common features between all types of platelet concentrates, while future research should focus on
identifying the role of the leukocytes and leukocyte-derived growth factors and cytokines in L-PRF.
To our knowledge, reports on the secretome-mediated effects of L-PRF on chondrocytes in vitro are
limited. Injectable-PRF, generated by a low speed centrifugation approach, was found to counteract
IL-1β inflammatory effects in chondrocytes [36]. In addition, Wong et al. treated chondrocytes with
different concentrations of PRF CM and showed a proliferative effect on chondrocytes and induced
chondrogenic differentiation of chondrocytes [37]. Moreover, Barbon et al. revealed that pre-clinical
studies strongly indicate a significant enhancement of cartilage regeneration after PRF treatment [34].
There are several reasons for the discrepancy in outcomes between our study and studies proving
beneficial effects of PRP or PRF in OA. One crucial factor might the inter-donor variability. Second,
as previously mentioned, platelet concentrates differ in growth factor kinetics, release levels and
amount of leukocytes. In addition, absolute platelet, white blood cell and red blood cell concentrations
can vary in different preparations.
In the present study, we show that the CM of DPSCs significantly enhances iMAC survival and
proliferation in vitro. DPSC CM exerts the same, but smaller, effects on TNF-α and IL-1β-stimulated
iMAC viability although not reaching statistical significance. DPSCs secrete various growth factors and
cytokines, which might be accountable for the observed outcomes in the present study. Previous studies
revealed high expression levels of TGFs and neurotrophic factors, including VEGF [20,89,90].
Other factors present in the DPSC secretome involve but are not limited to IL-8, MCP-1, FGFs,
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MMPs, TIMP-1 [18,20,91]. The presence of large quantities of VEGF in DPSCs could predominantly be
responsible for the proliferative effects on iMACs [78]. Narcisi et al. report that TGF-β1-stimulated
chondrocytes evidenced increased mRNA levels for several hypertrophy-specific markers, including
MMP-13, VEGF and TIMP-3 [92]. In our study, RT-qPCR data show that DPSC CM induced significantly
increased TIMP-1 expression in stimulated iMACs. TIMP-1 directly inhibits the activities of MMPs,
thereby contributing to reducing the impact of MMPs [93,94]. Next to this, in cytokine-stimulated
chondrocytes cultured on DPSC CM a not significant trend towards increased PGE2 production was
observed. The role of PGE2 is controversial in OA; though PGE2 exerts catabolic functions in OA,
one of the main effectors of MSC-mediated immune-suppression is PGE2 [95].
Cartilage-specific ECM production of iMACs in 3D culture after exposure to the secretome of L-PRF
and DPSCs was also evaluated. The benefit of using these micromass cultures compared to monolayer
cultures is that the 3D setting is more representative of the in vivo microenvironment. In consistence
with our RT-qPCR results, cytokine stimulation of iMACs induced meaningfully less production of PGs
and GAGs in micromass cultures, accompanied by increased nitrite secretion. Cartilage lacunae were
more preserved by 3% L-PRF ex, 25% L-PRF CM and DPSC CM with a weak tendency of improved
ECM content and chondrocyte status as compared to the stimulated control. Moreover, DPSC CM
significantly decreased nitrite levels of iMACs cultured in 3D micromasses. It should be noted that the
experiments in this study were conducted between 24–72 h post-stimulation, a time window in which
the outcome on matrix components like aggrecan or collagen type II production is not yet observed.
Therefore, we also evaluated fast acting proteins such as nitrite and PGE2. Nonetheless, subsequent
studies are necessary to investigate the impact on the structural level of cartilage by means of longer
in vitro cultures, cartilage-explant studies and in vivo experiments. Given the pathophysiology of OA,
the role of immune cells, other cell types present in the synovial joint and synovial joint structures
should ideally also be taken into account. Therefore, in order to supply a proper in vitro OA model,
the interchange of immune cells, the synovial membrane and subchondral bone with the cartilage
tissue and chondrocytes needs to be addressed. One-dimensional cell culture models cannot fully
mimic the complexity of the OA pathophysiology. However, several advantages are associated with
monolayer or one-dimensional cell cultures such as a large number of cells can be easily isolated,
and cells in monolayer permit the homogenous spread of cytokines and nutrients. Still, co-cultures
or 3D cultures permit the study of cell-specific changes and cell–cell communications, while explant
models inform on the induced alterations occurring in the ECM. The co-culture of the synovium with
chondrocytes is one way to reproduce the complexity of the pro-inflammatory events in vitro. The use
of bone in co-culture experiments is also crucial [96]. Haltmayer et al. utilised a co-culture system with
all three principal tissues involved in OA, such as cartilage, subchondral bone and the synovium [97].
5. Conclusions
The present study aimed to investigate the chondrogenic potential of both L-PRF and DPSCs
in vitro in terms of being able to replace lost cartilage tissue, while having chondroprotective and
immunomodulatory influences in OA chondrocytes. We show a discrepancy between BM-MSCs
and DPSCs to form neo hyaline cartilage in vitro and that L-PRF did not improve or impede the
chondrogenic differentiation of both DPSCs and BM-MSCs. However, DPSCs generated a GAG-
and collagen-rich matrix, demonstrating that DPSCs are a promising cell source to make cartilage
regeneration achievable. L-PRF CM exerted significant pro-survival and proliferative effects on
chondrocytes and increased several inflammation-related mediators involved in OA. Nevertheless,
transformation into hypertrophic chondrocytes remains an important matter that needs to be further
elucidated. Our data show promising therapeutic effects of DPSCs to repair cartilage lesions and in
an in vitro model mimicking OA, as they can potentially replace the damaged cartilage tissue and
act via secretome-mediated effects. On the one hand, DPSC CM can stimulate endogenous cells to
proliferate and replace the lost tissue, while on the other hand, it could prevent the progression of
cartilage loss by impairing chondrocyte apoptosis. Moreover, we indicate that factors secreted by
Cells 2020, 9, 980 18 of 23
DPSCs might cause multiple anti-inflammatory and anti-catabolic influences in OA chondrocytes.
Insights in the paracrine effects of DPSCs and understanding stem cell modulation will offer researchers
a number of treatment options for musculoskeletal diseases and traumatic injury that have until now
been limited by cell sourcing concerns. Finally, the influence of secretome-mediated actions of L-PRF
and DPSCs on OA chondrocytes and other types of cells or joint structures involved in OA should
additionally be investigated in longer-term co-culture systems or 3D cell culture settings. Furthermore,
since hypertrophic chondrocytes are important in pathological modifications in OA, a future study to
investigate the dedifferentiated or hypertrophic state of chondrocytes is warranted.
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